Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 083 • 2020 Pediatric Rheumatology Symposium
Worsening Disease Activity and Inability to Taper Corticosteroids in an Ethnically Diverse Cohort of Pediatric-Onset Lupus Patients After Transition to Adult Care
Marla Guzman¹, Anne Eberhard ¹ and Joyce Hui-Yuen ², ¹Cohen Children's Medical Center, Lake Success, ²Cohen Children's Medical Center, New Hyde Park
Background/Purpose: Transition of pediatric lupus (pSLE) patients from pediatric to adult rheumatology care is historically difficult and challenging. We aim to investigate disease activity and…
Abstract Number: 094 • 2020 Pediatric Rheumatology Symposium
A Good Inter- and Intra-observer Reliability of Subtypes in Nailfold Capillary Micro-haemorrhages in Childhood-onset Systemic Lupus Erythematosus
Sandy Bergkamp¹, Dieneke Schonenberg-Meinema ², Merlijn van den Berg ², Vanessa Smith ³, Amber Vanhaecke ⁴, Karin Melsens ⁴, Amara Nassar Sheikh Rashid ⁵, Taco Kuijpers ⁶ and Maartje Boumans ⁷, ¹Amsterdam Medical Center, Uithoorn, Netherlands, ²Amsterdam, Netherlands, ³Ghent University Hospital, Ghent, Belgium, ⁴Ghent University, Ghent, Belgium, ⁵Amsterdam Medical Center, Amsterdam, Netherlands, ⁶AMC, Amsterdam, Netherlands, ⁷Maxima Medical Center, Eindhoven, Netherlands
Background/Purpose: In previous studies, micro-haemorrhages have often been observed in nailfold capillaroscopy in SLE.1 The interpretation of this finding is still a topic of research.…
Abstract Number: 124 • 2020 Pediatric Rheumatology Symposium
Pharmacist Role in an Outpatient Adolescent Complex Pediatric Lupus Clinic
Shannon Rotolo ¹, Grace Cameron², Cuoghi Edens ¹ and Constentina Talevski ³, ¹UCM, Chicago, ²UCM, Oak Lawn, ³Univeristy of Chicago Medicine, Lockport
Background/Purpose: Systemic lupus erythematous (SLE) is an autoimmune disease in which the body produces pathogenic autoantibodies that cause inflammation resulting in multi-organ damage. A SLE…
Abstract Number: 127 • 2020 Pediatric Rheumatology Symposium
Disease Characteristics and Medication Utilization in Lupus Nephritis Associated with Childhood-Onset Systemic Lupus Erythematosus
Emily Smitherman¹, Rouba Chahine ¹, Timothy Beukelman ¹, Laura Lewandowski ², AKM Fazlur Rahman ¹, Scott Wenderfer ³, Aimee Hersh ⁴ and Jeffrey R Curtis ⁵ for the CARRA investigators, ¹University of Alabama at Birmingham, Birmingham, ²NIAMS, NIH, Rockville, ³Section of Nephrology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, ⁴University of Utah Primary Children's Hospital, Salt Lake City, ⁵University of Alabama at Birmingham, Hoover
Background/Purpose: Lupus nephritis associated with childhood-onset systemic lupus erythematosus (cSLE) is a significant risk factor for long-term morbidity and mortality, but little is known regarding…
Abstract Number: 128 • 2020 Pediatric Rheumatology Symposium
Predictors of Moderate/High Disease Activity in Childhood-Onset Systemic Lupus Erythematosus
Emily Smitherman¹, Rouba Chahine ¹, Timothy Beukelman ¹, Andrea Knight ², AKM Fazlur Rahman ¹, Mary Beth Son ³, Jeffrey R Curtis ⁴ and Aimee Hersh ⁵ for the CARRA investigators, ¹University of Alabama at Birmingham, Birmingham, ²SickKids Research Institute, Toronto, Canada, ³Boston Children's Hospital, Boston, Massachusetts, ⁴University of Alabama at Birmingham, Hoover, ⁵University of Utah Primary Children's Hospital, Salt Lake City
Background/Purpose: Substantial risk of early morbidity and mortality exists for patients with childhood-onset systemic lupus erythematosus (cSLE), but there are limited studies identifying predictors of…
Abstract Number: 151 • 2020 Pediatric Rheumatology Symposium
Differences in Chromatin Architecture Between Treatment-Naïve Pediatric and Adult Lupus Patients
Joyce Hui-Yuen¹, Frank Jenkins ², Kaiyu Jiang ³, Betty Diamond ² and James Jarvis ⁴, ¹Cohen Children's Medical Center, New Hyde Park, ²Northwell Health, Manhasset, ³University at Buffalo, Buffalo, ⁴University at Buffalo Jacobs School of Medicine, Buffalo
Background/Purpose: Systemic lupus erythematosus (SLE) is possibly triggered by gene-environment interactions. We showed most of the SLE haplotypes contain epigenetic marks associated with enhancer function…
Abstract Number: L15 • 2019 ACR/ARP Annual Meeting
Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor, Fenebrutinib (GDC-0853), in Moderate to Severe Systemic Lupus Erythematosus: Results of a Phase 2 Randomized Controlled Trial
David Isenberg¹, Richard Furie ², Nicholas Jones ³, Pascal Guibord ⁴, Joshua Galanter ⁵, Chin Lee ³, Anna McGregor ³, Balazs Toth ³, Julie Rae ³, Olivia Hwang ³, Pedro Miranda ⁶, Viviane de Souza ⁷, Juan Jaller-Raad ⁸, Anna Maura Fernandes ⁹, Rodrigo Garcia Salinas ¹⁰, Leslie Chinn ³, Michael Townsend ¹¹, Alyssa Morimoto ³ and Katie Tuckwell ¹², ¹University College London, London, United Kingdom, ²Northwell Health, Great Neck, NY, ³Genentech, Inc., South San Francisco, California, ⁴Hoffmann-La Roche Limited, Mississauga, Canada, ⁵Genentech, Inc., SOUTH SAN FRANCISCO, ⁶Centro Estudios Reumatologicos, Santiago, Chile, ⁷Centro Mineiro de Pesquisas, Juiz de Fora, Minas Gerais, Brazil, ⁸Centro de Reumatologia y Ortopedia, Cimedical, Barranquilla, Colombia, ⁹Mario Covas Hospital, Santo Andre, Sao Paulo, Brazil, ¹⁰Hospital Italiano de La Plata, La plata, Buenos Aires, Argentina, ¹¹Genentech, Inc., San Fransisco, ¹²Genentech, Inc., South San Francisco, CA
Background/Purpose: Fenebrutinib (GDC-0853, FEN) is an oral, non-covalent, and highly selective inhibitor of Bruton’s tyrosine kinase (BTK) in clinical development for autoimmune diseases. The efficacy,…
Abstract Number: L18 • 2019 ACR/ARP Annual Meeting
A Human Recombinant Fusion Protein Targeting B Lymphocyte Stimulator (BlyS) and a Proliferation-Inducing Ligand (APRIL), Telitacicept (RC18), in Systemic Lupus Erythematosus (SLE): Results of a Phase 2b Study
Di Wu¹, Jing Li ², Dong Xu ², Wenxiang Wang ³, Lin Li ⁴, Jianmin Fang ³ and Fengchun Zhang ⁵, ¹Peking Union Medical College Hospital, Beijing, Beijing, China (People's Republic), ²Department of Rheumatology and Clinical Immunology Peking Union Medical College Hospital, Beijing, China (People's Republic), ³RemeGen, Ltd., Yantai, China (People's Republic), ⁴RemeGen, Ltd., Beijing, China (People's Republic), ⁵Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (People's Republic)
Background/Purpose: Telitacicept, also named RC18, is a novel recombinant fusion protein constructed with the extracellular domain of the human transmembrane activator and calcium modulator and…
Abstract Number: 98 • 2019 ACR/ARP Annual Meeting
Selective Induction of Functional Regulatory T-Cells in Healthy Volunteers by NKTR-358, a Novel IL-2 Conjugate Treg Stimulator, in Development for the Treatment of Autoimmune Diseases
Christie Fanton¹, Neha Dixit ¹, Suresh Siddhanti ¹, Lin Lu ¹, Daniel Dickerson ², Brian Kotzin ¹ and Jonathan Zalevsky ¹, ¹Nektar Therapeutics, San Francisco, ²PRA Health Sciences, Lenexa
Background/Purpose: Regulatory T cell (Treg) dysfunction and impaired IL-2 production have been implicated as key immunological defects in multiple autoimmune diseases. Enhanced sensitivity of Tregs…
Abstract Number: 677 • 2019 ACR/ARP Annual Meeting
Performance of Montreal Cognitive Assessment (MoCA) in Screening for Cognitive Impairment in Patients with Lupus Compared to the Neuropsychological Battery
Mahta Kakvan ¹, Robin Green ², Lesley Ruttan ³, Maria Tartaglia ⁴, Joan Wither ⁵, Moe Zandy ¹, Dennisse Bonilla ¹, May Choi ⁶, Jiandong Su ¹, Marvin Fritzler ⁶, Dorcas Beaton ⁷ and Zahi Touma¹, ¹University Health Network, University of Toronto, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³Toronto Rehabilitation Institute, Toronto, Canada, ⁴University Health Network, University of Toronto, Toronto, ON, Canada, ⁵University Health Network, Krembil Research Institute, Toronto, ON, Canada, ⁶Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁷St. Michael's Hospital, Toronto, ON, Canada
Background/Purpose: Cognitive impairment (CI) is a common neuropsychological manifestation of Systemic Lupus Erythematosus (SLE) with a prevalence of 38% [95% confidence interval: 33,43%]. Previous studies,…
Abstract Number: 897 • 2019 ACR/ARP Annual Meeting
Mortality Rates After Coronary Revascularization Procedures Among Systemic Lupus Erythematosus Compared to Diabetes Mellitus and General Population Medicaid Patients
Medha Barbhaiya¹, Sarah Chen ², Candace Feldman ³, Hongshu Guan ³, Brendan Everett ⁴ and Karen Costenbader ⁴, ¹Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ²Brigham and Women's Hospital and Harvard Medical School, Boston, ³Brigham and Women's Hospital, Boston, ⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: Despite similar myocardial infarction risks in SLE and diabetes mellitus (DM) patients, individuals with SLE enrolled in Medicaid had substantially higher rates of coronary…
Abstract Number: 1097 • 2019 ACR/ARP Annual Meeting
Trends in NSAIDs and Opioids Among Patients with SLE: A Population-based Study
Lingyi Li¹, Na Lu ¹, Jacek Kopec ², John Esdaile ³, Hui Xie ⁴ and J. Antonio Avina-Zubieta ², ¹Arthritis Research Canada, Vancouver, BC, Canada, ²Arthritis Research Canada and the University of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Canada and the University of British Columbia, Richmond, BC, Canada, ⁴Arthritis Research Canada and Simon Fraser University, Vancouver, BC, Canada
Background/Purpose: Non-steroidal anti-inflammatory drugs (NSAIDs) and opioids are prescribed for the management of pain among patients with rheumatic diseases including systemic lupus erythematosus (SLE). However,…
Abstract Number: 1562 • 2019 ACR/ARP Annual Meeting
The Association of Body Weight Fluctuation and All-Cause Mortality in Patients with Systemic Lupus Erythematosus
Sarah Bayefsky¹, Alyson Dickson ¹, Tyler Reese ¹, Jocelyn Gandelman ², Megan Shuey ¹, April Barnado ¹, Katherine Barker ¹, C. Michael Stein ¹, Vivian Kawai ¹ and Cecilia Chung ¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University School of Medicine, Nashville, TN
Background/Purpose: Recent studies have suggested that body weight fluctuation in the general population is an independent risk factor for overall mortality. These findings are of…
Abstract Number: 1604 • 2019 ACR/ARP Annual Meeting
The Systemic Lupus Erythematosus Cardiovascular Risk Equation
Michelle Petri¹, Erik Barr ² and Laurence Magder ², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Accelerated atherosclerosis remains the major cause of late death (after 5 years) in systemic lupus erythematosus (SLE). Yet, the "traditional" cardiovascular risk equations (such…
Abstract Number: 1763 • 2019 ACR/ARP Annual Meeting
A Phase 3 Randomized Controlled Trial of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus
Richard Furie¹, Eric Morand ², Ian Bruce ³, Susan Manzi ⁴, Kenneth Kalunian ⁵, Edward Vital ⁶, Theresa Lawrence-Ford ⁷, Ramesh Gupta ⁸, Falk Hiepe ⁹, Mittermayer Santiago ¹⁰, Philip Brohawn ¹¹, Anna Berglind ¹² and Raj Tummala ¹³, ¹Zucker School of Medicine at Hofstra/Northwell, New York, NY, ²Monash University, Melbourne, Victoria, Australia, ³University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, ⁴Allegheny Health Network, Pittsburg, PA, ⁵Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ⁶University of Leeds, Leeds, United Kingdom, ⁷North Georgia Rheumatology, Lawrenceville, GA, ⁸Baptist Memorial Hospital-Memphis, Memphis, TN, ⁹Charité University Hospital Berlin, Berlin, Germany, ¹⁰Bahiana School of Medicine and Public Health, Bahia, Brazil, ¹¹AstraZeneca, Gaithersburg, MD, ¹²AstraZeneca, Gothenburg, Sweden, ¹³AstraZeneca, Gaithersburg, MD, USA, Gaithersburg, MD
Background/Purpose: In a phase 2 study in SLE patients (pts), substantial efficacy was observed with anifrolumab, a human monoclonal antibody that binds the type I…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].